tetano
Editor, Senior Moderator
Nano Today
. 2022 Dec 21;48:101730.
doi: 10.1016/j.nantod.2022.101730. Online ahead of print.
A Highly Efficient Needle-Free-Injection Delivery System for mRNA-LNP Vaccination against SARS-CoV-2
Shanhong Mao[SUP] 1 2 [/SUP], Shiyou Li[SUP] 3 [/SUP], Yuxin Zhang[SUP] 4 [/SUP], Luoxin Long[SUP] 1 [/SUP], Junfeng Peng[SUP] 3 [/SUP], Yuanyan Cao[SUP] 1 [/SUP], Jessica Z Mao[SUP] 5 [/SUP], Xin Qi[SUP] 4 [/SUP], Qi Xin[SUP] 3 [/SUP], Guoliang San[SUP] 4 [/SUP], Jing Ding[SUP] 4 [/SUP], Jun Jiang[SUP] 3 [/SUP], Xuejiao Bai[SUP] 3 [/SUP], Qianting Wang[SUP] 3 [/SUP], Pengfei Xu[SUP] 3 [/SUP], Huan Xia[SUP] 3 [/SUP], Lijun Lu[SUP] 3 [/SUP], Liangzhi Xie[SUP] 6 [/SUP], Desheng Kong[SUP] 6 [/SUP], Shuangli Zhu[SUP] 7 [/SUP], Wenbo Xu[SUP] 7 [/SUP]
Affiliations
Abstract
Despite the various vaccines that have been developed to combat the coronavirus disease 2019 (COVID-19) pandemic, the persistent and unpredictable mutations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require innovative and unremitting solutions to cope with the resultant immune evasion and establish a sustainable immune barrier. Here we introduce a vaccine-delivery system with a combination of a needle-free injection (NFI) device and a SARS-CoV-2-Spike-specific mRNA-Lipid Nanoparticle (LNP) vaccine. The benefits are duller pain and a significant increase of immunogenicity compared to the canonical needle injection (NI). From physicochemical and bioactivity analyses, the structure of the mRNA-LNP maintains stability upon NFI, contradictory to the belief that LNPs are inclined towards destruction under the high-pressure conditions of NFI. Moreover, mRNA-LNP vaccine delivered by NFI induces significantly more binding and neutralizing antibodies against SARS-CoV-2 variants than the same vaccine delivered by NI. Heterogeneous vaccination of BA.5-LNP vaccine with NFI enhanced the generation of neutralizing antibodies against Omicron BA.5 variants in rabbits previously vaccinated with non-BA.5-specific mRNA-LNP or other COVID-19 vaccines. NFI parameters can be adjusted to deliver mRNA-LNP subcutaneously or intramuscularly. Taken together, our results suggest that NFI-based mRNA-LNP vaccination is an effective substitute for the traditional NI-based mRNA-LNP vaccination.
Keywords: Lipid Nanoparticle (LNP); Needle injection (NI); Needle-free injection (NFI); SARS-CoV-2; mRNA vaccine.
. 2022 Dec 21;48:101730.
doi: 10.1016/j.nantod.2022.101730. Online ahead of print.
A Highly Efficient Needle-Free-Injection Delivery System for mRNA-LNP Vaccination against SARS-CoV-2
Shanhong Mao[SUP] 1 2 [/SUP], Shiyou Li[SUP] 3 [/SUP], Yuxin Zhang[SUP] 4 [/SUP], Luoxin Long[SUP] 1 [/SUP], Junfeng Peng[SUP] 3 [/SUP], Yuanyan Cao[SUP] 1 [/SUP], Jessica Z Mao[SUP] 5 [/SUP], Xin Qi[SUP] 4 [/SUP], Qi Xin[SUP] 3 [/SUP], Guoliang San[SUP] 4 [/SUP], Jing Ding[SUP] 4 [/SUP], Jun Jiang[SUP] 3 [/SUP], Xuejiao Bai[SUP] 3 [/SUP], Qianting Wang[SUP] 3 [/SUP], Pengfei Xu[SUP] 3 [/SUP], Huan Xia[SUP] 3 [/SUP], Lijun Lu[SUP] 3 [/SUP], Liangzhi Xie[SUP] 6 [/SUP], Desheng Kong[SUP] 6 [/SUP], Shuangli Zhu[SUP] 7 [/SUP], Wenbo Xu[SUP] 7 [/SUP]
Affiliations
- PMID: 36570700
- PMCID: PMC9767897
- DOI: 10.1016/j.nantod.2022.101730
Abstract
Despite the various vaccines that have been developed to combat the coronavirus disease 2019 (COVID-19) pandemic, the persistent and unpredictable mutations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require innovative and unremitting solutions to cope with the resultant immune evasion and establish a sustainable immune barrier. Here we introduce a vaccine-delivery system with a combination of a needle-free injection (NFI) device and a SARS-CoV-2-Spike-specific mRNA-Lipid Nanoparticle (LNP) vaccine. The benefits are duller pain and a significant increase of immunogenicity compared to the canonical needle injection (NI). From physicochemical and bioactivity analyses, the structure of the mRNA-LNP maintains stability upon NFI, contradictory to the belief that LNPs are inclined towards destruction under the high-pressure conditions of NFI. Moreover, mRNA-LNP vaccine delivered by NFI induces significantly more binding and neutralizing antibodies against SARS-CoV-2 variants than the same vaccine delivered by NI. Heterogeneous vaccination of BA.5-LNP vaccine with NFI enhanced the generation of neutralizing antibodies against Omicron BA.5 variants in rabbits previously vaccinated with non-BA.5-specific mRNA-LNP or other COVID-19 vaccines. NFI parameters can be adjusted to deliver mRNA-LNP subcutaneously or intramuscularly. Taken together, our results suggest that NFI-based mRNA-LNP vaccination is an effective substitute for the traditional NI-based mRNA-LNP vaccination.
Keywords: Lipid Nanoparticle (LNP); Needle injection (NI); Needle-free injection (NFI); SARS-CoV-2; mRNA vaccine.